Moshe Rogosnitzky is a research scientist, innovator and inventor of major medical breakthroughs, and consultant to oncology specialists, patients and companies. His extraordinary career has spanned multiple disciplines and has produced ground-breaking cancer and auto-immune disease treatments. His belief that medicine and science should deliver rapid and tangible benefits to the patient has been the driving force behind all his accomplishments.

Research Scientist

Rogosnitzky has a long history of highly rewarding collaborations and joint research projects with leading academic institutions including:

  • Johns Hopkins University (Baltimore MD)
  • University Hospital of Lille (France)
  • Hershey Medical Center (Penn State University)
  • Hadassah University Hospital (Jerusalem)
  • St. George’s University Hospital (London)
  • University of Southern California.
  • Rogosnitzky has published significant medical research in multiple fields including autoimmune disease (Crohn’s Disease), cancers (breast, prostate, skin, liver and pancreatic cancer), abdominal surgery, hemostasis, and eye disease.

    Rogosnitzky has served as peer reviewer for numerous medical journals including:

  • International Immunopharmacology (Elsevier)
  • Molecules (MDPI)
  • The Journal of Molecular Diagnostics (American Society for Investigative Pathology – ASIP)
  • World Journal of Surgical Oncology (Springer)
  • Fibrogenesis & Tissue Repair (BioMed Central)
  • Evidence-Based Complementary & Alternative Medicine journals
  • He has also served as a grant-reviewer for the Crohn's & Colitis Foundation of America (CCFA).

    Medical Innovator

    His pioneering work has also resulted in the development of new treatments for various types of cancer. His highly promising treatment for Crohn's disease using Low Dose Naltrexone (LDN) has completed Phase I and II trials, and has been licensed to Cytocom Inc. (soon entering Phase III trials). He has also developed the first-ever non-surgical treatment for a common eye condition known as pterygium.

    An innovator in both targeted and off-label uses of medications, Rogosnitzky holds intellectual property rights in numerous fields including:

  • Prostate cancer
  • Crohn’s disease
  • Ulcerative colitis
  • Opthalmology
  • Hemostasis
  • Androgenic alopecia
  • Medical-information systems.
  • Consultant

    Numerous Champions Oncology VIP Expert Opinion Panel conferences have sought his expertise spanning multiple cancer types (including pancreatic, lung, esophageal, metastatic melanoma, and sarcoma).

    He is regularly invited to lecture at conferences in North America and Asia, and has guest lectured for the Israeli Government Ministry of Health.

    Rogosnitzky is the founder and director of the world’s first academic drug repurposing center at Ariel University, Israel and also consults to companies seeking his expertise in drug re-purposing.

    Philanthropist and Teacher

    Since 1999 Moshe’s personalized medical consultations with cancer patients have focused on utilizing highly specialized genomic diagnostics to achieve high-impact treatment strategies. In that time, panels of oncology specialists have regularly sought his expertise.

    Moshe believes that patients should have the knowledge to make informed decisions about their health. He oversees the synthesis of published medical research into comprehensive, consumer-friendly summaries through his work as Co-Founder and Research Director of the non-profit MedInsight Research Institute.

    He works tirelessly as founder and executive director of We Fund The Cure, a non-profit organization that has been at the forefront of facilitating research of new uses for existing drugs since 2009.

    He also created LDNscience.org – the largest physician and patient public information site for Low Dose Naltrexone (LDN) – a drug now used by more than 300,000 patients world-wide.

    Moshe Rogosnitzky is an autodidact with no formal secondary education. He believes his outstanding achievements reflect to a great extent the freedom he has enjoyed to think independently.